Selank: Anxiolytic and Nootropic Peptide

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from tuftsin (Thr-Lys-Pro-Arg), an endogenous immunomodulatory tetrapeptide, with the addition of a Pro-Gly-Pro sequence that confers resistance to enzymatic degradation and extends the compound's biological half-life.

Selank was originally investigated for its immunomodulatory properties but was subsequently found to produce anxiolytic and nootropic effects in rodent behavioral models. This dual profile — immune modulation combined with central nervous system activity — makes it an unusual compound that bridges two traditionally separate research domains.

The peptide has a molecular weight of approximately 751.9 Da and is water-soluble. It has been studied primarily in Russian academic institutions, with a growing body of international research exploring its mechanisms and applications in behavioral neuroscience.

Selank's mechanism of action involves multiple pathways, reflecting its structural origin as both an immunopeptide and a CNS-active compound.

**GABAergic modulation:** Preclinical studies indicate that Selank influences GABAergic neurotransmission. In rodent brain tissue, it has been shown to modulate the expression of GABA-A receptor subunit genes, particularly in limbic structures associated with anxiety-related behavior. This modulation is thought to underlie its anxiolytic effects, though it operates through a distinct mechanism from benzodiazepines — Selank does not appear to bind directly to the benzodiazepine site on the GABA-A receptor.

**Monoamine metabolism:** Selank affects serotonin metabolism in rodent brain models. Studies have reported changes in the ratio of serotonin to its metabolite 5-HIAA in the hypothalamus and hippocampus following Selank administration, suggesting modulation of serotonergic turnover. Dopamine and norepinephrine metabolism are also influenced, though the effects appear region-specific and concentration-dependent.

**Immunomodulation:** Via its tuftsin-derived core, Selank modulates innate immune function. It enhances phagocytic activity and influences cytokine expression profiles, including IL-6 and TNF-alpha, in peripheral immune cell models. This immunomodulatory activity is particularly relevant for research exploring the neuroimmune interface.

**Gene expression:** Microarray studies in rodent hippocampal tissue have identified broad gene expression changes following Selank administration, including upregulation of BDNF (brain-derived neurotrophic factor) and genes involved in neurotransmitter receptor signaling.

The majority of Selank research has been conducted in rodent behavioral and molecular models.

Selank and Semax are frequently discussed together as they were developed at the same institution and share a similar research history, but they are distinct compounds with different targets.

**Selank** is tuftsin-derived and primarily modulates GABAergic and serotonergic systems. Its predominant preclinical effects are anxiolytic, with secondary nootropic and immunomodulatory activity. It is most relevant for research into anxiety-related behavior and the neuroimmune interface.

**Semax** is ACTH-derived (a fragment of adrenocorticotropic hormone) and primarily modulates BDNF expression and monoaminergic neurotransmission. Its predominant preclinical effects are neuroprotective and cognitive-enhancing. It is most relevant for research into neuroprotection and cognitive function.

In some preclinical protocols, the two peptides have been studied in combination, as their distinct mechanisms may produce complementary effects on CNS function. However, the interaction pharmacology is not yet well characterized, and most published studies examine each compound independently.

Selank presents several unique considerations for study design:

**Route of administration:** Most rodent studies use intranasal or intraperitoneal routes. Intranasal delivery is of particular interest because it may provide more direct access to the CNS via the olfactory epithelium, bypassing first-pass metabolism. Studies comparing routes suggest that intranasal administration produces behavioral effects at lower total concentrations.

**Stability:** Selank is more resistant to enzymatic degradation than its parent compound tuftsin, thanks to the Pro-Gly-Pro extension. However, reconstituted solutions should still be stored at 2-8°C and used within 14 days. Lyophilized material is stable at -20°C for 12-18 months.

**Behavioral testing timing:** Anxiolytic effects in rodent models are typically assessed 15-30 minutes after administration. Nootropic effects require repeated administration protocols (typically 5-7 days) before testing.

**Controls:** Because Selank influences both immune and neural endpoints, appropriate control groups should include vehicle controls and, ideally, reference compounds for the specific pathway under investigation (e.g., diazepam for anxiolytic comparison, tuftsin for immunomodulatory comparison).

*All materials are for research use only.*